Nasdaq Stsa News Today

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi purchased 22,053,581 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was bought at an average price of $0.91 per share, for a total transaction of $20,068,758.71. Following the purchase, the director now directly owns 24,847,694 shares in […]

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) and Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation. Earnings & Valuation This table compares Satsuma Pharmaceuticals and […]

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 130,100 shares, a decrease of 58.0% from the April 30th total of 310,100 shares. Approximately 0.5% of the shares of the stock are sold […]

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 130,100 shares, a decline of 58.0% from the April 30th total of 310,100 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is […]

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) and Catalent (NYSE:CTLT – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership. Earnings and Valuation This table compares Satsuma Pharmaceuticals and Catalent’s revenue, […]

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) and Catalent (NYSE:CTLT – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Volatility and Risk Satsuma Pharmaceuticals has a beta of 0.1, indicating […]

NEA Management Company LLC lessened its position in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) by 4.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,992,958 shares of the financial services provider’s stock after selling 150,000 shares during the […]

HC Wainwright cut shares of Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) from a buy rating to a neutral rating in a report released on Tuesday morning, The Fly reports. Separately, Mizuho reaffirmed a neutral rating and set a $2.00 target price on shares of Satsuma Pharmaceuticals in a research report on Thursday, March 30th. Four […]

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 159,400 shares, a decrease of 40.4% from the March 15th total of 267,500 shares. Based on an average daily trading volume, of 152,700 shares, the short-interest ratio […]

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, The Fly reports. Separately, Mizuho restated a “neutral” rating and set a $2.00 price objective on shares of Satsuma Pharmaceuticals in a […]